Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Business Overview and Product Portfolio
AMGN logo

Amgen's Revenue Up 7% to $28.19B in 2023, Horizon Acquisition Boosts Rare Disease Portfolio

AMGN10-KFiling Date: 2/14/2024
Amgen Inc.
Description

What this story covers

Amgen's 2023 revenue grew 7% to $28.19B, driven by strong product sales and the $27.8B Horizon acquisition, despite rising operating costs and increased debt. R&D spending hit $4.8B, fueling a robust pipeline and biosimilar development.

Story snapshot

CompanyAmgen Inc.
TickerAMGN
VariantStandard detailed
Duration15:43
Filing type10-K
PeriodAnnual 2023
IndustryHealthcare & Pharmaceuticals
Accession0000318154-24-000011

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in